ADC Therapeutics (ADCT) Q3 2024 Earnings
ADCT·Reported November 7, 2024·Before market open
ADC Therapeutics reported Q3 2024 revenue of $18.5M, missed analyst consensus of $18.8M by $385.7K. Diluted EPS came in at $-0.42, missed the $-0.36 consensus by $0.06.
Revenue
$18.5Mmissed by $385.7K
Consensus: $18.8MDiluted EPS
$-0.42missed by $0.06
Consensus: $-0.36
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about ADC Therapeutics's Q3 2024 earnings report.
ADC Therapeutics (ADCT) reported Q3 2024 earnings on November 7, 2024 before market open.
ADC Therapeutics reported revenue of $18.5M and diluted EPS of $-0.42 for Q3 2024.
Revenue missed the consensus estimate of $18.8M by $385.7K. EPS missed the consensus estimate of $-0.36 by $0.06.
You can read the 10-Q periodic report (0001628280-24-046050) directly on SEC EDGAR. The filing index links above go to sec.gov.